# Emergence Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/emergence-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Duisburg, Germany
- Website: www.emergencetx.com
- Total disclosed funding: $98M
- Latest round: Series A (Dec 5, 2021)
- Investors on record: 13

## About

Founded in 2019 and based in Duisburg, Germany, Emergence Therapeutics AG is a developer of novel antibody-drug conjugate immuno-therapeutics intended to treat cancer. The company uses ATAC technology to target Nectin-4 providing doctors and healthcare organizations with an effective drug as a therapy tool to treat cancer.

## Funding rounds

- Series A, Dec 5, 2021, $98M — OrbiMed Advisors, NRW Bank, Pontifax Venture Capital, Kurma Partners, Surveyor Capital, High-Tech Gruenderfonds, RA Capital Management, Bpifrance Investissement, Hadean Ventures, Grunderfonds Ruhr
- Seed, Nov 25, 2020 — Idinvest Partners, NRW Bank, Kurma Partners, High-Tech Gruenderfonds, Bpifrance, Unzer GmbH

## Investors

- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Seed
- NRW Bank — Seed, Series A
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Seed, Series A
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series A
- Bpifrance — Seed
- Unzer GmbH — Seed
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A
- Surveyor Capital — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A
- Hadean Ventures (https://capitalatlas.ai/funds/hadean-ventures) — Series A
- Grunderfonds Ruhr — Series A